An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.

Trial Profile

An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Chemotherapy-induced damage; Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin Korea
  • Most Recent Events

    • 15 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top